DLEU2L

Across TCGA pan-cancer cohorts, DLEU2L mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of DLEU2L’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where DLEU2L mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types DLEU2L is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

CCRCC, HNSC, and COAD are the cancer types where DLEU2L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DLEU2L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	−0.732	<.001	12	view →
HNSC	Male	II,III,IV	+0.519	<.001	8	view →
COAD	All	All	+0.314	.004	7	view →
PDAC	Female	II,III,IV	+0.597	.010	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

DLEU2L–CCRCC

Open the CCRCC breakdown →